---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-160355"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:31:21.332589+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics prices $150M stock offering; provides Haduvio trial updates

## Summary
- Offering of 11.6M shares at $13.00/sh; net proceeds ~$141.1M (or ~$162.4M if option exercised).
- Cash, cash equivalents and marketable securities ~$171.8M as of March 31, 2026.
- Cash runway extended through 2029, funding two Phase 3 IPF-cough trials and Phase 2b in non-IPF ILD and RCC.
- First Phase 3 IPF trial starts Q2 2026; topline results expected H1 2028; second Phase 3 in H2 2026 with results H2 2027.
- Phase 2b for RCC begins Q2 2026, topline results H2 2027.

## SEC filing metadata
- accession: 0001193125-26-160355
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/0001193125-26-160355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/d587027d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-160355
- JSON: https://secwatch.observer/filing/0001193125-26-160355.json
- Plain text: https://secwatch.observer/filing/0001193125-26-160355.txt

## Source-grounded claims
- claim_id: 7e6a4b7f3990c0f142ba7ec8f77e0465cafab62c
  claim: Trevi Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $13.00 per share (effective 2026-04-16).
  evidence_excerpt: On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/0001193125-26-160355-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.